PMID- 24709887
OWN - NLM
STAT- MEDLINE
DCOM- 20141228
LR  - 20191210
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 24
IP  - 3
DP  - 2014 Jun
TI  - Value of dopachrome tautomerase detection in the assessment of melanocytic 
      tumors.
PG  - 219-36
LID - 10.1097/CMR.0000000000000066 [doi]
AB  - Dopachrome tautomerase (DCT) and tyrosinase (Tyr) are melanogenic enzymes and 
      structurally related melanosomal proteins. The present study investigates DCT 
      expression comparatively with Tyr, the most tested melanoma biomarker, aiming to 
      evaluate DCT potential in the assessment of melanocytic tumors and gain insights 
      into the molecular and pathological characterization of DCT-phenotype in tumor 
      progression. DCT and Tyr are simultaneously analyzed in melanoma cell lines by 
      semiquantitative RT-PCR, western blot, and N-glycan analysis, and in cell 
      populations of melanocytic tumors by immunohistofluorescence using a novel 
      anti-hDCT antibody against an extended sequence within DCT luminal domain. DCT, 
      unlike Tyr, is fully processed along the secretory pathway in both pigmented and 
      amelanotic melanoma cells. In 53 nevi and 116 primary malignant melanomas, 81% 
      and 52%, respectively, are DCT+/Tyr+, showing that DCT is a stable antigen, 
      retained by most tumors and partially expressed in Tyr-negative cell populations. 
      The DCT/Tyr disjunction is a process correlated with melanocyte neoplastic 
      transformation and malignant progression. A tumor 
      architecture--DCT-phenotype-containing DCT+/Tyr- cell populations selected into 
      the innermost dermis from double-positive cells is detected in 35% of DCT+/Tyr+ 
      specimens. The DCT-phenotype is associated with enhanced neurotization in benign 
      nevi and with ulceration in thin malignant melanomas. The intradermal DCT+/Tyr- 
      clones in superficial melanomas acquire the expression and specific subcellular 
      distribution of unfavorable prognostic markers. DCT assessment shows specific 
      antigen patterns with potential significance in the outcome of melanocytic 
      lesions, connecting DCT, a mediator of a melanoma stress-resistant pathway, and 
      an antiapoptotic molecule to DCT- phenotypes that are possibly more stable and 
      stress resistant.
FAU - Filimon, Anca
AU  - Filimon A
AD  - Departments of aMolecular Cell Biology bBioinformatics and Structural 
      Biochemistry, Institute of Biochemistry, Romanian Academy cDepartment of 
      Pathology, Colentina University Hospital, Bucharest, Romania.
FAU - Zurac, Sabina A
AU  - Zurac SA
FAU - Milac, Adina L
AU  - Milac AL
FAU - Sima, Livia E
AU  - Sima LE
FAU - Petrescu, Stefana M
AU  - Petrescu SM
FAU - Negroiu, Gabriela
AU  - Negroiu G
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Biomarkers, Tumor)
RN  - EC 1.14.18.1 (Monophenol Monooxygenase)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.3.12 (dopachrome isomerase)
SB  - IM
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Fluorescent Antibody Technique
MH  - Gene Expression Regulation, Enzymologic
MH  - Gene Expression Regulation, Neoplastic
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Humans
MH  - Intramolecular Oxidoreductases/genetics/*metabolism
MH  - Melanocytes/*enzymology/pathology
MH  - Melanoma/*enzymology/genetics/pathology
MH  - Monophenol Monooxygenase/metabolism
MH  - Nevus, Pigmented/*enzymology/genetics/pathology
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - RNA Interference
MH  - Skin Neoplasms/*enzymology/genetics/pathology
MH  - Transfection
EDAT- 2014/04/09 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/04/09 06:00
PHST- 2014/04/09 06:00 [entrez]
PHST- 2014/04/09 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - 10.1097/CMR.0000000000000066 [doi]
PST - ppublish
SO  - Melanoma Res. 2014 Jun;24(3):219-36. doi: 10.1097/CMR.0000000000000066.